Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Myeloproliferative Disorders 2Stomach Neoplasms 1Recurrence 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Eosinophilia 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

Paclitaxel 19pembrolizumab 16Carboplatin 12Bevacizumab 8lenvatinib 6rucaparib 5Nivolumab 5Megestrol Acetate 5Radiation 4Indocyanine Green 4Gemcitabine 4Cisplatin 4tisotumab vedotin 3temsirolimus 3Sirolimus 3Sentinel Lymph Node Biopsy 3Magnetic Resonance Spectroscopy 3Doxorubicin 3olaparib 2niraparib 2ixabepilone 2iso-sulfan blue 2irosustat 2epacadostat 2durvalumab 2copanlisib 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Neoplasms × pemigatinib × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡